Guggenheim Lifts PT on Johnson & Johnson (JNJ) to $167 From $164, Keeps a Neutral Rating

Johnson & Johnson (NYSE:JNJ) is one of the top low volatility healthcare stocks to buy now. On July 17, Guggenheim raised the firm’s price target on Johnson & Johnson (NYSE:JNJ) to $167 from $164, keeping a Neutral rating on the shares.

The firm gave the price target upgrade after Johnson & Johnson (NYSE:JNJ) delivered a “strong” Q2 and gave an “encouraging outlook” for its growth prospects in the second half of the year.

Guggenheim justified a Neutral rating on the stock by stating that it is waiting for increased visibility on the emerging Innovative Medicine pipeline that will need to offset Stelara’s decline.

Johnson & Johnson (NYSE:JNJ) reported a 5.8% sales growth in Q2 2025 to $23.7 billion, with operational growth of 4.6% and adjusted operational growth of 3.0%. The company also raised its 2025 outlook, increasing full-year estimated reported sales guidance at the midpoint by $2 billion to 5.4% and full-year EPS guidance by $0.25 to $10.85.

This increase was supported by favorable foreign exchange results and strong operational performance by the company.

Johnson & Johnson (NYSE:JNJ) develops, manufactures, and sells products in the healthcare field. The company operates through two segments: Innovative Medicine and MedTech.

The MedTech segment includes an elaborate range of medical devices and products used in cardiovascular intervention, orthopedics, interventional solutions, surgery, and vision fields.

While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.